Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase

BACKGROUND: Direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C infection (HCV) globally. Exploratory studies to identify potential rare adverse drug events associated with DAAs to optimize their use are scarce. OBJECTIVE: We aimed to describe the most common serious DAA-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Kaleen N., Burkard, Theresa, Weiler, Stefan, Tadrous, Mina, Burden, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2021
Materias:
Short Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734625/
https://www.ncbi.nlm.nih.gov/pubmed/33883523
http://dx.doi.org/10.1097/MEG.0000000000002173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734625/
https://www.ncbi.nlm.nih.gov/pubmed/33883523
http://dx.doi.org/10.1097/MEG.0000000000002173

Ejemplares similares